Hematology Advisor

Among patients with severe #hemophilia A and B, treatment with the monoclonal antibody marstacimab has been associated with reduced rates of bleeding. From @RareDisease_Adv. bit.ly/3Up1ntE

Subcutaneous isatuximab administered via an on-body injector appears to be as safe and effective as intravenous isatuximab in patients with R/R #multipleMyeloma. Presented at @EHA_Hematology conference #EHA2025. bit.ly/46jn1qB

"Women with cancer who are considering #FertilityPreservation before initiating cancer treatment should not be dissuaded or discouraged from an attempt at #OvarianStimulation,” said @PennMedicine's Alison Wakoff Loren, MD. @HematologyAdv spr.ly/601744Zuh

In the phase 3 LUNA3 study, rilzabrutinib led to rapid and durable platelet response and demonstrated a favorable safety profile in heavily pretreated adults with persistent or chronic #ITP. Published in @BloodPortfolio. bit.ly/46TuCfx

The final analysis of the phase 3 BELLINI trial demonstrated that the addition of venetoclax to bortezomib and dexamethasone failed to prolong OS compared with placebo plus bortezomib and dexamethasone among patients with R/R #multipleMyeloma. Published in @TheLancetHaem.…

C-reactive protein levels are found to be increased among #caregivers of persons with a primary malignant #braintumor, highlighting the role of this biomarker as an indicator of psychological stress. Published in @Cancer_Nursing and @ONAcom. bit.ly/4lFdONA

Researchers have reported a case of recurrent primary central nervous system #lymphoma that demonstrated only mild 18F-FDG PET uptake on relapse. From @RareDisease_Adv. bit.ly/4kz1o91 #PCNSL #lymsm

The prices charged at the US launch of targeted #cancer therapies have increased well above the rate of inflation every year since 2012. Published in @JAMA_current and @CancerTherAdvsr. bit.ly/4lRtzky

A large consortium study suggests that the use of second-line EMs or SMIs may yield optimal outcomes among patients with R/R mature TNKLs. bit.ly/4nPhFJL #lymphoma #lymsm

A Landmark Update: @ASH_hematology and @isth Release First Pediatric VTE Guidelines Since 2018 @HematologyAdv hemostasistoday.com/organizations/… #ASH #BloodAdvances #Health #Hematology #HematologyAdvisor #HemostasisToday #ISTH #Medicine #PediatricVTE #MedEd #medX

📰 Check it out! The @ASH_hematology and ISTH Updated Guidelines on the Treatment of Pediatric VTE are featured in @HematologyAdv. Don’t miss this spotlight on our collaborative effort! 📖 Read the full feature: hematologyadvisor.com/news/pediatric… #PediatricVTE #Hematology #ISTH

An initiative aimed at improving the health care transition for young patients with #sickleCellDisease appeared to demonstrate success in reaching goals across a network of centers. Reported in @JAMANetworkOpen. bit.ly/4lugVYY #SCD

The TyG index is an accurate and useful tool for prognostic assessment in #DLBCL. Published in @FrontiersIn Endocrinology. bit.ly/4lc8C3W #lymsm

The combination of low-dose nivolumab with bendamustine in treatment of children with high-risk R/R classical #HodgkinLymphoma appeared to be associated with favorable survival and response outcomes. Reported in @BrJHaem. bit.ly/407skpa #lymsm

The @FDA has granted accelerated approval to Lynozyfic™ for the treatment of adult patients with R/R #multipleMyeloma who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody. From…

Long-term treatment with hydroxyurea has sustained clinical benefits, including reduced emergency department visits and hospital days, for children living with #sickleCellDisease. Published in @BloodAdvances. bit.ly/4kllUtD #SCD

Adding polatuzumab vedotin to treatment with R-GemOx can improve survival outcomes in patients with R/R diffuse large B-cell #lymphoma. Presented at @EHA_Hematology conference #EHA2025. bit.ly/4lLWJSn #DLBCL #lymphsm

C-reactive protein levels are found to be increased among #caregivers of persons with a primary malignant #braintumor, highlighting the role of this biomarker as an indicator of psychological stress. Published in @Cancer_Nursing and @ONAcom. bit.ly/4lFdONA #CancerCare

Among fit, elderly patients with #AML, venetoclax plus modified intensive chemotherapy may lead to remission in approximately 75% of cases. Published in @BloodAdvances. bit.ly/44yMk5q #leusm

Among patients with R/R #multipleMyeloma, a therapeutic combination including salvage high-dose chemotherapy, ASCT, and lenalidomide maintenance does not appear to improve OS outcomes. Published in @BloodPortfolio. bit.ly/44Dio8i